Neumora Therapeutics, Inc. (NASDAQ:NMRA) is one of the best stocks under $5 with the highest upside potential. Needham raised its price target on NMRA to $8 from $6 with a Buy rating after a positive R&D Investor Event showcasing its broad pipeline. Guggenheim upgraded NMRA to Buy with a $14 price target due to compelling preclinical obesity data.

Neumora Therapeutics, Inc. (NASDAQ:NMRA) focuses on integrating neuroscience and data science to offer precision medicine for brain diseases. They are a clinical-stage biotechnology company advancing medicines for CNS diseases. Investors are optimistic about NMRA’s outlook, especially after positive data reports and upgrades from analysts.

While NMRA shows promise, some AI stocks may offer greater upside potential with less downside risk. For investors interested in undervalued AI stocks benefiting from tariffs and onshoring trends, consider exploring the best short-term AI stock. Check out Insider Monkey for more insights on potential stock picks and market trends.

For more stock recommendations and hidden AI gems, check out Insider Monkey’s articles on 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. Find the original article on Insider Monkey for more information.

Read more at Yahoo Finance: Needham Lifts PT on Neumora Therapeutics (NMRA) to $8 From $6, Keeps a Buy Rating